ALX Oncology
Founded Year
2015Stage
IPO | IPOTotal Raised
$123.02MDate of IPO
7/17/2020Market Cap
0.44BStock Price
8.84About ALX Oncology
ALX Oncology is a clinical-stage biotechnology company that focuses on immuno-oncology within the healthcare sector. The company develops therapies that block the CD47 checkpoint pathway, bridging the innate and adaptive immune system to help patients fight cancer. Their lead product, evorpacept, is a next-generation CD47 blocking therapeutic designed to have a high affinity for CD47, aiming to block the 'don't eat me' signal on cancer cells and leverage the immune activation of broadly used anti-cancer agents. ALX Oncology was formerly known as Alexo Therapeutics. It was founded in 2015 and is based in Burlingame, California.
Loading...
Loading...
ALX Oncology Patents
ALX Oncology has filed 24 patents.
The 3 most popular patent topics include:
- clusters of differentiation
- monoclonal antibodies
- immunology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/7/2020 | 5/2/2023 | Monoclonal antibodies, Clusters of differentiation, Experimental cancer drugs, Immunology, Monoclonal antibodies for tumors | Grant |
Application Date | 1/7/2020 |
|---|---|
Grant Date | 5/2/2023 |
Title | |
Related Topics | Monoclonal antibodies, Clusters of differentiation, Experimental cancer drugs, Immunology, Monoclonal antibodies for tumors |
Status | Grant |
Latest ALX Oncology News
Nov 14, 2023
ALX Oncology press release (NASDAQ: ALXO ): Q3 GAAP EPS of -$1.24 misses by $0.37. Non-GAAP net loss was $44.0 million for the third quarter ended September 30, 2023, as compared to a non-GAAP net loss of $29.1 million for the third quarter ended September 30, 2022. Cash, cash equivalents and investments as of September 30, 2023, were $196.4 million. ALX Oncology believes its cash, cash equivalents, and investments along with the ability to draw down an additional $40 million of its term loan and the net proceeds from its recent public offering are sufficient to fund planned operations into early 2026.
ALX Oncology Frequently Asked Questions (FAQ)
When was ALX Oncology founded?
ALX Oncology was founded in 2015.
Where is ALX Oncology's headquarters?
ALX Oncology's headquarters is located at 866 Malcolm Road, Burlingame.
What is ALX Oncology's latest funding round?
ALX Oncology's latest funding round is IPO.
How much did ALX Oncology raise?
ALX Oncology raised a total of $123.02M.
Who are the investors of ALX Oncology?
Investors of ALX Oncology include venBIO, Lightstone Ventures, BVF Partners, Foresite Capital, HBM Healthcare Investments and 6 more.
Loading...
Loading...